COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00633282
Recruitment Status : Completed
First Posted : March 12, 2008
Last Update Posted : June 5, 2012
Shanghai Jiao Tong University School of Medicine
Shanghai Municipal Science and Technology Commission
Information provided by (Responsible Party):
Xin Gao, Fudan University

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Completed
Actual Primary Completion Date : August 2011
Actual Study Completion Date : August 2011
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 18, 2013
November 5, 2013
2 March 5, 2019
June 7, 2019

Publications automatically indexed to this study by Identifier (NCT Number):